country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

41 Results for "

BID

" in MedChemExpress (MCE) Product Catalog:

Products (41)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

(±)-BI-D

6 Cited Publications

Cat. No.: HY-18601

CAS No.: 1416258-16-6

Target:

HIV HIV Integrase

Research Areas:

Infection

(±)-BI-D is a potent ALLINI (allosteric integrase inhibitor). (±)-BI-D binds integrase at the LEDGF/p75 binding site. (±)-BI-D inhibits HIV-Luc infection in cells (IC₅₀: 0.16 μM in Psip1 knockout E9 mouse embryonic fibroblasts, 2.9 μM in wild-type E9 mouse embryonic fibroblasts) .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

BI-D1870

23 Publications Verification

Cat. No.: HY-10510

CAS No.: 501437-28-1

Purity: 99.43%

Target:

Ribosomal S6 Kinase (RSK) Autophagy

Research Areas:

Cancer

BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of RSK isoforms, with IC₅₀s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Niflumic acid

6 Cited Publications

Cat. No.: HY-B0493

CAS No.: 4394-00-7

Target:

Chloride Channel COX

Research Areas:

Inflammation/Immunology Cancer

Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC₅₀ value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

BI-6C9

3 Cited Publications

Cat. No.: HY-103661

CAS No.: 791835-21-7

Purity: 98.47%

Target:

Mitochondrial Metabolism Apoptosis

Research Areas:

Neurological Disease

BI-6C9 is a highly specific BH3 interacting domain (Bid) inhibitor, which prevents mitochondrial outer membrane potential (MOMP) and mitochondrial fission, and protects the cells from mitochondrial apoptosis inducing factor (AIF) release and caspase-independent cell death in neurons .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Edelfosine

1 Cited Publications

Cat. No.: HY-108610A

CAS No.: 70641-51-9

Purity: ≥99.0%

Synonyms: ET-18-OCH3

Target:

Apoptosis Parasite Bcl-2 Family Cytochrome P450

Research Areas:

Infection Inflammation/Immunology Cancer

Edelfosine (ET-18-OCH3) is an orally active lipid raft modulator and apoptosis inducer that alters membrane fluidity and preferentially inserts into tumor cell membranes. Edelfosine recruits death receptor ligands (FasL/CD95L, TRAIL) and Bid to lipid rafts to form death-inducing signaling complexes, thereby initiating mitochondria-dependent apoptosis and inducing cytochrome c release. Edelfosine also exerts anti-inflammatory effects, promotes L-Selectin shedding, and causes no gastrointestinal or organ toxicity. In addition, Edelfosine inhibits nucleic acid and protein synthesis in Leishmania donovani and exhibits antiproliferative activity. Edelfosine can be used in research on multiple myeloma, inflammatory bowel diseases (such as ulcerative colitis and Crohn's disease), and visceral leishmaniasis .

Compare